This could accelerate the trend towards greater accessibility, a critical development in the obesity and diabetes treatment space
GLP-1s are shaping how people eat, drink, shop, and exercise, and brands need to be paying close attention to these trends. Also referencing the KFF survey, Shil Kothari, president at Gateway Health Alliances Inc., Fairfield, Calif., explains that the awareness of GLP-1s mean that beverage manufacturers must play a proactive role in offering solutions that support those using these medications
The patients who took GLP-1s may have had access to better health care and a lower risk of cancer to begin with, he said
However, in clinical practice higher doses up to 2.0 mg are used in patients with T2D, and up to 2.4 mg/week in patients with obesity without T2D